RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth-Reference-Cited by-同舟云学术

RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth

Published:2019-03-04 Issue:4 Volume:129 Page:1641-1653
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:

Author:

Umesalma Shaikamjad,Kaemmer Courtney A.,Kohlmeyer Jordan L.,Letney Blake,Schab Angela M.^ORCID,Reilly Jacqueline A.,Sheehy Ryan M.,Hagen Jussara,Tiwari Nitija,Zhan Fenghuang,Leidinger Mariah R.,O’Dorisio Thomas M.,Dillon Joseph,Merrill Ronald A.^ORCID,Meyerholz David K.^ORCID,Perl Abbey L.,Brown Bart J.,Braun Terry A.^ORCID,Scott Aaron T.,Ginader Timothy^ORCID,Taghiyev Agshin F.^ORCID,Zamba Gideon K.,Howe James R.,Strack Stefan^ORCID,Bellizzi Andrew M.^ORCID,Narla Goutham^ORCID,Darbro Benjamin W.,Quelle Frederick W.^ORCID,Quelle Dawn E.

Funder

NIH

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://www.jci.org/articles/view/123049/files/pdf

Reference81 articles.

1. NANETS Consensus Guidelines for the Diagnosis of Neuroendocrine Tumor

2. One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States

3. Multimodal management of neuroendocrine liver metastases